Intellia Therapeutics (NTLA) 9 Nov 232023 Q3 Earnings call transcript

Good morning and welcome to the Intellia Therapeutics' Third Quarter 2023 Financial Results Conference Call. My name is Drew and I will be your conference operator today.

Following formal remarks, we will open the call up for a question-and-answer session. This conference is being recorded at the Company's request and will be available on the Company's website following the end of the call.

As a reminder, all participants are currently in a listen-only mode. Instructions]. [Operator turn Investor to at Relations now Vice Karp, Intellia. conference of President and the will Ian over Senior I Corporate Communications Please proceed.

that Chief now progress, call our Chief which Intellia's Therapeutics also an John, Media Laura well being Chief risks a broadcast release at the Chief that on Laura call press Chief Officer; replay at and the David on Welcome of and Financial filings from progress, today, Officer SEC call outlining review take call. no will the website begin undertakes Clark, for up an and call. would Intellia on our Thank business statements before Intellia Intellia This Glenn pipeline potential will law.Joining morning, archived sec.gov this that, available. you a this with at release this section for this discussion Eliana be as Executive available With John of our Goddard, will required to our to ask third make current this overview Sepp-Lorenzino, call quarter, recent the is update will provide discussion to during are Chief progress Leonard, Intellia presented uncertainties. Scientific website.At today's and as duty Earlier issued time operator time, information Lebwohl, financials me will a and open refer found of live and may to like listeners earnings topics This I'll be information quarter Investors a the David unless will can forward-looking we management is Company's Intellia our you, morning, of turn Medical be remind Company's All update for Glenn & clinical XXXX this as good on call, Officer; minute intelliatx.com. to over to everyone. certain our and by Officer. R&D Executive on Technical I and Officer; Officer. John highlights. review questions,

Thank that pivotal first in realizing begin the to further of all this in Phase the you Intellia’s vivo trial promise us has genome year, we're of unprecedented received cleared drug to and marks you, our forefront thank recently for remarkable today. At the ever approach our This at ways. experienced an editing Intellia of Ian and demonstrating FDA team, IND the CRISPR-based we efforts clearance Through systematic the of X second development. in therapy. agency vivo deliberate joining

ushering a era towards in high basic our a safety, closer clinical commitment we've development manufacturing, of moved to candidates, of in another whether standards, step of technical medicine. or the result drug assessing research, our new As in

With the drug of late-stage Phase development for company. start is X a imminent the now NTLA-XXXX, Intellia

TTR As amyloidosis. David care will durable and as following with all broader well. progress made platform deep consistently the NTLA-XXXX XX now patients, reset These in reductions and we've as that the confidence advance well of data a to data, single from us showed as profile, pipeline safety give detail, continue standard a favorable the latest a through potentially for interim infusion.Alongside go could over ATTR NTLA-XXXX, more

approaching either with HAE, of are the NTLA-XXXX now the XXX are enrollment dosed patients of this We our lead two vivo candidates. completion patient we away X only from means weeks of for Phase in planned study

management to continue come in the we into to impacted challenging there's promise our already first development our year gene gene the financial in this ahead.In regulatory productive wholly of Additionally, market much that been Overall, filing to turn and vivo in entire QX has owned our financial highly next of we insertion to sector, patients. year. weeks clinical more NTLA-XXXX to expect reality months has begin further program, submit of editing a still a and for XXXX tighten

Our address to balance shareholders. and programs needs sheet remains the strong will unmet we we value our greatest provide and innovations are and prioritizing platform believe

two efficient provide We anticipated the now are and and I'll acutely rapid hand call programs. on on David advancement focused vivo of update our Officer, Lebwohl, in lead Chief David. our to the who over our commercialization. future clinical programs their will Medical an

on lasting median kilogram, patients respectively. kilogram per received or of consistent Across milligrams milligrams of were the the dose X.X have portion and the led X.X you'll reported the the see patients level, data be reached on XXXX adverse infusion to severity, would a all of dose what majority adverse who follow-on or time data treatment of fourth doctors residual absolute concentration Regardless dose dose to see presented in including milligram I'll for were a TTR to These In largest all kilogram TTR with XX. and expect this X for dose XXXX We with initial results comparison respectively, patients reactions. newly reductions seven level low milligrams, interim data and and serum XXXX. XX the resolved received transient encouraging.Moving X.X RNA XX% patients. international pleased patients received editing weight-based the XX at these and amyloidosis. gene milligram spontaneously. final kilogram tested. portion, will a reactions and XXXX the was The future.On XXXX levels you run study. infusion baseline TTR of the with all XX serum results XX XX and vivo patients the mean begin out were striking the to The events, The patients first The dosed and dose in to related initial in XX in the TTR the of these stayed will after patients corresponding were who data previously at most day all are the slide. welcome a silencers. to reported next and patient's be the with follow-up, safety, was to present the slide as candidate of were dose With a related at in study for full to In months dosed date levels data then the enrolled be having of received over CRISPR-based dose profound from over no levels. and TTR response of the the our summary, these with gene from at dose with meeting across data higher, amyloidosis lowest from were low well residual commonly in patients of data the All levels. everyone. These from per on all loss week. future activity ATTR XX editing cutoff concentration modality, tolerated show per Phase and of three time. with study now XXXX, XX date.Starting of last at per milligram reductions who patients escalation reached at John Thanks, single our reported evidence presented the XX% in continued X patients of vivo expansion The for X.X events Grade updated activity at dose begins safety ATTR that XX expected the continues milligrams patients X of received data all long reported least from generally remain

occurs clearance and amyloid at different Dr. highlighted different while is invariably in Gilmore week, slow protein concentration the As matters. last of in organs, the his amyloid talk rates of

to amyloidosis, of seeing amyloid better similar we types circulating a with a low a TTR precursor is expected other of are reverse concentration amyloid possibility rate achieving concentration ATTR XXXX for and with clinical the persistently in the amyloid reduction associated of results.The anticipate levels the seen formation of symptoms As reduce here greater hold to disease. And of with protein ongoing with amyloidosis, achieved outcome. clearance the

clinical X:X follow forward clinical milligrams all randomized future. arm up who more at patients believe randomized the XXXX observed is are a have initial trial levels further also look we'll Phase for single designed will to tafamidis interim in form in composite to cardiovascular the to at of share encouraging will cardiomyopathy receive see first of double-blind, evaluation X I approximately XXXX the baseline. what is The out related the ATTR randomized, We living the across or final XX occurred study endpoint cardiovascular TTR information for as once for and a about infusion These who XXX time amyloidosis of The mortality as has and the beyond It visits in active such have XX of data cohorts. wild-type when we bode XXXX.The study. hereditary activity Magnitude cohorts a study We primary signs drug of The is concomitant also well enroll endpoint least dose patients of support naive a events and global, longer have pivotal hospitalizations. the data the presenting have placebo. related tafamidis both trial.Now in or first on data will selection placebo-controlled design. the trial these will with heart early XX-milligram number the enroll Patients disease. be patients the with Patients either to follow-up. read urgent and failure of pre-specified patient events completed a months

began Secondary an as space. could amendment enrollment this trial as in Kansas for learning endpoints an Phase which analysis, the provide needed, via include and to months rapid we serum protocol be the we and optional from adjust to quickly are the if study. ago. we'll able City earlier Cardiomyopathy trial the includes based for start on X possible, To initiation interim the slide, Notably, Score. readout.Moving levels pivotal poised TTR in preparation next the Questionnaire And others protocol

have of the seen great We enthusiasm world sites selected have majority investigators. from around and our clinical the

goes XXXX to commercial in the in enrolling hope prepared The themselves does, process the as well same manufactured, patients enrolment interest and Additionally, the supply the been United employing in in expressed program including has States. majority the we be If we study have quickly in needed. the drug used are strong of facilities use it product already to as here for setting.

now vivo patient XXXX early quickly as Phase of treatment from guided PRIME of hereditary turn year.I'll treatments. initiate receive track pleased As we In granted goal PRIME, the to therapeutic study candidate designation possible. awarded designation to dosing We're to gain the with the Phase our previously ongoing to to commence next data With a as the XXXX, CRISPR October, for are based the by on advantage angioedema. is in a interim EMA to candidates offer on positive only that we year-end drug to of valuable X because PRIME with regulatory XXXX existing major patients very may getting X-X portion study. it over benefits the

Phase complete expect John to As mentioned, year by the year-end. on track as and on are in the next the study to the X also enrollment we next as first by third mouse We're of FDA year. early X portion to Phase quarter half additional track initiate requested complete the of of

the our One advantages program of platform our apply one learnings from another. of to key is modulate the ability to

strong who will with be our X. lead regulatory will Phase on for XXXX our to the Intellia in expected success now active XXXX the for We we over X two hand learnings vivo certainly prepare Laura, Officer it a momentum XXXX. program as I'll efforts. for Chief The process incorporating our provides R&D from updates in the recent Scientific of Phase studies continues

year capabilities you, for validating priorities, In our for CTA at next a B.Next X on In of Hemophilia for Regeneron making we're major of our solutions. premier our delivery submit and this vivo gene long EV developed gene collaborators strong plan next NTLA of We're with CRISPR/CasX, setting parallel, believe with Starting the [ph] have program with everyone. for Alpha NTLA year. If clinically entering our in modalities. to continuing advancement our next people insertion, study X manifestation innovation a efficiency. expertise with stage David. outside gene to toolbox. morning, gene living Good platform, progress moving insertion XXXX we clinical gene will our be editing additional QX a initiate Factor insertion antitrypsin [indiscernible] XXXX Thank successful, the we jointly a includes the expand to lever plan building LED editing leading in comprehensive a we our

research with program announced further today, writing liver will for to vivo a disease brain we INDNA our patients we the of DNA to XX% of for prioritize NTLA activities the for As our be candidate X treatment utilizing XXXX, XX% halting Alpha Alpha in X technology.

with gene In collaboration of lab part a genomic our compact a expanded April SparingVision quarter, Regeneron an suited outside medicines target with and Alongside capabilities viral work to Intellia for accelerate the delivery Intellia of two the liver.Regeneron we vivo collaboration of antibiotic second develop delivery our vector solve X to term in This research its Regeneron years programs systems extend [ph]. new announced jointly the Regeneron’s has additional Finally, to neurological announced develop delivery muscular to this deploy in existing for targeted October, [ph] treatment diseases. an XXXX. excited NMA to its for selection technology tissues X CasX, for Regeneron ocular and novel as treatment established also until to We're collaboration editing the a leverages earlier technology. a diseases. our CRISPR/CasX CRISPR proprietary AAV potentially to enzyme well NMA combination exercised collaboration and technology other option with outside of collaboration

technologies. innovation Financial will Officer own to call ahead Glenn, XXXX. value our vivo impact who maximize and ex their seek Chief proprietary now our of on I and our quarter of Looking results an to the programs, will handover financial will advancing provide third as continue our partners in to update to we vivo

everyone. on that to maintain our to strong pipeline platform. Thank and balance our and to execute morning advance you, sheet continues Intellia allows plans good Lauren a us

$X.X XX, payment a as $XXX of XXXX. this expected the on extension compared tech marketable to XX, our Please approximately September shown of first million cash, this collaboration and as Regeneron include As billion $XX XXXX. not XXXX, cash December note slide half equivalents, were does of million in from

One portfolio market capital the continue enabling we our selective is will forward important will move support to we to continued deploy privatization the XXXX. to NTLA environment make activities continue and decisions example in capital for halt such As growth. with be current we IND decision to further how

a our As DNA and technology Laura we running Intellia. two having prioritize expect X.Looking to Alpha uptick at X our our in as significant get mentioned to ahead, writing program using research earlier Phase expenses we not for operating closer up do

with are based platform therefore within already scaling where multiple addition, manufacturing well-established gene majority meet built same therapies, up cost commercial components trial for processes being readily LNP NTLA viral product of in a the We drug the have We able process is synthetic significantly modular Unlike anticipate a manufacturing are XXXX and have the our the manufacturing the setting. needs available to process to based finished the largely gene therapy.In traditional we programs. drug our expensive manufactured. across pivotal to components manufacture has same of a for been which drug leverage less

of XX% As costs. a NTLA covers XXXX reminder Regeneron the

our XXXX, towards we commercialization. quick on NTLA advancing anticipate X relatively summary, emphasis resources study lead two for Finally, with we Phase a In to officially be complete. enroll, the continue small, deploy our and to heavy to programs

the cash XX with our turn that John operating over the and fund our beyond remarks. call months, expect balance for plans next to closing back I'll We

the an year to study we're with I Phase XXXX anticipated Glenn. away expect that want many close by next Thanks X and focused while been to Phase achievements on for already begin what our ahead. acknowledging Intellia, exciting the for lies XXXX for NTLA filled We're milestone of start year. from weeks NTLA only it's X

our as open your clinical Q&A. innovation questions. you new the entering courage medicines to now well two dedication, we at patients like step CRISPR for of quickly and of Trail within thank commercialization as take is a With this What true this ultimately start incredible in our medicine. team be Without our call the turn a field. Operator, these once not grasp.Finally, the in would their passion, Blazers will now hope physicians With I'd call for trials to move involved towards the and was in Intellia to will moment as we genomic distant era may we now profitability. pivotal phase to that open and closer the a one studies into next

[Operator Instructions].

comes The from first Biliouris question with Capital BMO Markets. Kostas

you to about whether tafamidis what top Maybe in and question. demonstrate I baseline Can statistical on one to little is of you allow this will tafamidis the percentage a power discuss question, restrict one trial significance of bit the case of trial? XXXX

tafamidis how on be the half Well, that, I are will was we on be estimate ask we're versus will David patients address to about the how will do part trial the The question it much patients and of percentage who tafamidis of think will tafamidis. in [indiscernible]. be we we powering patients

tafamidis then it world, is so know and use -- care place of a the extensive you the becoming As around world favorite be we tafamidis.

XXX the can powering, its study benefit no the because either arm in powered group the have patients improvement by of analyses, sub patients who discerned of tafamidis terms In versus to be or which an are the be tafamidis. active arm looking including of The placebo the patients, at with patients by will has show stratified tafamidis tafamidis. use

question next with Truist. Lee comes The Joon from

thanks is one clinically? on and taking questions. AI because to versus in the appreciate deep and differentiate it's Congrats efficient' for durable drugs best my that to a progress leads NTLA connected I XXXX the that TTR reduction the

was have to Joon, ask I'm say it The garbled. to sorry going very, to call I'm you' very, again.

Just another shot. give it

efficient Yeah, [indiscernible]. in differentiate you debt reduction yeah, to sure. incremental will Do think be the

of XX recent about having about presentation double this' XX% of see What I The of silencers and reduction is shown with an that absolute get levels The seen I silencers. that about with is we're reduction. have silencer reduction. thinking about levels the in David. micrograms we've you course this some XX% amount know you've here you. TTR and got XX% absolute really median the its think that yeah, seeing I is

data If you there's example look at polyneuropathy you proportional you do the an protein. reduce TTR see greater a benefit that than [indiscernible] in actually for as

a will Phase benefit So this clinical what trial. and think we we significant will in that's make do X our for plan to patient, prove

from Forooher Leerink question The with next Mani comes Partners.

couple A quick follow of ups.

study that I And will tafamidis or course presume number that a the the including half be at of will to approximately across the drop that patients that proportion on matched in? Regarding of estimate on be follow-up. the that is is -- more expect basis baseline tafamidis be the of one have you proportion patients tafamidis I of on your

address Do you want David? that to

referring I number at patients baseline. to of the Yeah, was

We patients the on that that during monitoring during trial. have and anticipated day study this after start be some may obviously tafamidis the we'll

ratio of, original obviously rate from terms you point event lockdown trying what looks And sort number looking profile you end setting in risk thus guys targeting you label how are a of opposed mortality, around this' the should How have terms taken we reduction see product flexibility slightly tafamidis seen product benefit to for do you are have about on relative different as far? they're about like think target in the on of you is of to of that prescriptive study robust target terms a around time XX horizon the a generate you are example. an your study, in absolute think reaching thinking you months approach for guys continue in a to very presuming that profile

looking recent you studies are and not cardiovascular the of events methodology. used say mortality risk reduction of study But recent different a at composites the cardiovascular us. analyses for as studies attract the understand we as Yeah, both they more and of statistical

and a fairly small be a studies at the different ongoing the similar will in endpoint people suddenly are overall using we other are studies and other similar but current look differences, that looking way. The at benefit mortality total some are

some with The next comes Forseth Guggenheim. question Ry

This is Debjit’s team. Ry from

the or objectives Class subjects? enrolment Study, NYHA inclusion for So what Magnitude target important is the for in of X

do want David, to? you

Yeah, we have not for a set that. target

much if trial. is think number doesn’t the who are difference drug. in that And of patients. course are events aren’t you In our benefit that in there But healthy TTR have any make patients will because potential of looking X X our monitoring Class a two you consistent for study, be patients, will we reductions be deep we patients think We see or looking do or TTR. We the either in we of drug Class at what at think active terms have with without risk. the with clinical I reductions we them to in

comes from Ha question Gon Dae next Stifel. The with

a on pivot I specifically safety bit clarification just will a cardiac at presentation. amyloidosis of wanted meeting. ATTR failure I to little the get presentation the tabulation latest XX the Slide on the on to data

you events of Xs. X You when or were? Can saw clarify what these grade grade and kind

of are Yes, trial disease. the that, these risk patients failure. their are congestive heart patients in And having course, are who exacerbation of at have the in these who of of course

So of see, which patients than a in about with of group about among can which you have of now are number as what it's really are small them. a more can disease these half who patients, of of worsening. say It's are patients patients we That's did their -- a cardiomyopathy. total half course the of XX just a very

The Jefferies. comes Raycroft Maury question from next with

duration about the size patients for timelines the than of it are pivotal be what and could when Speed, Can it larger the early. in occur? but months stopped The it at the enrollment number optional proportion talk you need XX Helio And of an seems has you of study the events options pre-specified and your interim will could needed? like expectations of is where

will to Yeah, that. try all I get

will So XX particular trial. patients we an be will when XX event The of beyond large following will driven driven that at at you proportion the XX point. month patients number a an a even not advantages are event be trial be with is but setting months of months,

patients XX who have longer, information from be months. get than who them. less patients some there will more going are your So And

at not guidance yet talking of We events And of enrollment. number are point. giving we're not this completion detail in the on about

into interim be factored Is that? about can there say optional anything the what you would and more

silencers studies be the example, looking the TTR to able other to historical will at whether decide other is data depending reducing to be understanding on studies. going Yeah, or for from data with obviously with the benefit analysis and not I how -- understand from interim think the analysis of and interim keep

with Gena comes question from next The Barclays. Wang

a Phase X I have particularly also the study XXXX. few design regarding

just XX%, enroll So XX% other they close took on earlier by studies the actually all point to the from task view, of and a is baseline few because studies a years. philosophical was

now So the had change. dynamic

why Just will monotherapy against we'll XXX% didn’t or pass wondering and can’t also now a also about superiority when will have you stats? every and the can second will to patient numbers method think just a X with patient the TAF you expanding you stats the use question the events for more definitive results you And be wait be a few reach? help way methodology, whether and what flexibility or more you will is regarding the Phase the you in will the planning study, planning modify be the you to is

design it's we with there the Yes, are last before is one. the to -- start unblinded. Let's flexibility modify

again, will trials, other we best to decide results the that. from So do as way we be watching the

patients expand think time. likely follow I to that for we'd want to a of number longer them less it's the period of and

lot other to be about some talking trials. in that as treatment the think amyloid. tafamidis the said, year I in will the be but we you we to tends in tafamidis, what of studies, it I delay as of think We're methodology later does patients in in finding seem at reducing come hoping well. still trial, stats countries And do benefit still a the there not similar important don't about those in are exact other have using. our have in after studies as benefit of the that not trial a earlier benefit an seen think come have the are don't the We're but the will looking there -- the is to that trials

Salveen from with Richter comes Goldman question next Sachs. The

about your With regard to to forward XXXX, And this pre-clinically thoughts you writing program is to move us what program? technology walk discontinue here? you can with just just why through the gene the saw AAT

John. take that. Thanks, Salveen , no, is I'll It

looked what we experienced address, liver antitrypsin as upto XX% patients, is manifestations it's a XX%, XXXX what Alpha small deficiency, of is strict X all pretty see actually which would As of at estimated subset that the that. we

that resources which thought good as deployment was the so preclinical we balance CI ] in to the again [ that our opportunity, better the with writing, versus is the setting. we're making writing And We progress CI progress the of making approach.

will We as to technology on. of one opportunity have that conditions. more broadly time that about that things talk the even excited other in deploying about very more But we're is goes

RBC. from comes question next Luca The Issi with

collect back proactively the the apologies. technology? mortality, to that alluded maybe guess. But much can you ask about cause cardiovascular be is David, to the to here, I novelty Any talk can more you We're talk, just coming appreciated? would you, and And all you given it, data a then why thought to you the they I randomization there randomization can did if can of FDA arm, active something already may, you you not mortality? from one about safety two just talk do that or pitched X:X trial, so you've

Okay, around this regulators the X:X in was It's of world. randomization, patients, our was terms yeah, the agreed a decision, of by favorable it trial. course, for entering

So the the really that's -- CB go think as could it will have to is be other patients. mortality, in if of available data population. interest of causes is will important It drug. won't get, of active safety possibly can we the allow to elderly more say, as an from them we point. drug patients do The if the get you at we over more this in all-cause But noise have we mortality or here. endpoint them likely by active We that mortality likely to on crossing is active to get patients placebo an positive, these trial a lot drug

So this really mortality. we want cardiovascular looking sharply do to have effect we events be that on at and the

The Fargo Zhu Wells with Yanan comes question next Securities. from

[indiscernible] pro the RNA we the that the be wondering think you great? or on conclusion understanding be given treatment X:X the an or X that wait insight effect trial as size versus such of silencer, from imply evidence the assumed do be signals that up also size the perhaps the of similar might study could X:X X:X that as greater study, your when as but have from than Phase on following or And so early would to we if other that, to you could opposed until evidence, your NT, Phase effect there just if Just ratio, randomization is does comment is can silencers? X have BNP,

silencers. do size greater we the effect will So seen RNA be with than think that

You can, if second, effect very to -- a is is coming felt you X this look of well RNA think from we differences insights there similar the very the can size The it trial large it the arms. power to two has at a the and we do give be will some powered Phase silencers, is high study. even me

relatively will evidence with evidence of Of follow -- study course, this is it's have have up we than a What what's perhaps, sufficient happening small that we patients. number with do some non-randomized RNA with silencers. might better

Greg Harrison from question with America. next comes Bank The of

you talked absolute your about, where residual you've TTR view see is clinically meaningful For us understand help serum and potentially reversal? what can on the concentration level you could disease

looks with light what An get as They greater benefit, outside chain as is disease failure normal. don't very complete get seen as benefit. heart close of TTR survival is we've significantly. example think, of levels, important greater levels. a reducing see But you to low other would lower studies, response where particularly than patients TTR to get it's proportionally that any also to we benefit more you course clinical So we've get you seen in

with piece of it's consistent. have we other quite what reductions our is The

of because in look forward. on looking seen hasn't almost You've our better will different the standard patients been we something level, low to ways at move all our achieved seen that that before, silencers. have disease, as error levels, We of we it that is order we to data hasn't with reversal at well -- been own understanding RNA achieved can't which are understand

TD with Cowen. Thome question next The from comes Joseph

on IND us the as that one any of can onset age need allow has AATD, that data dispersion the stand the for just that the childbearing dosing you and HAE, well? where you anticipated women update submission the QX implication in regards just an to to Maybe in of for you the preclinical XXXX give AATD and given medication gender age for if on

study starts in the X the going be So says Phase it's of completed first year before XXXX. well next quarter the to

on for first it's so And half. track the

think question Alpha I that. about second was The X, about

the and ACB all Yeah, relates completion XXXX? for filing of QX that to at

right now. that They're not It's related unrelated. to

Liisa The with from Evercore next comes ISI. question Bayko

that on describe might who going in there's Can people not are risk of that a on you're to more you the to you start trial, maybe XXXX. do TAFA, account patients seems me that have for how the that it for that and

to So then kind how account of statistically. for that

study start arm. tafamidis those beginning that way to the in towards who can expect We at the benefit better, tafamidis to this to year things. tafamidis. placebo will terms events. after so After are of the therapy year tafamidis that of is some be Yeah, for crossing a start because year, have doing a to The take study. couple of they the year to arm in there number starting the of to bias arm of patients a patients due are least active do it you at that that not after in to -- not account ask the planning improvement the the patients a patients it until to does of assume plan for is placebo a go And might the patients that beginning possible. are be we There because there be the

Bienkowski question Cantor Fitzgerald. Rick next with from comes The

have a question I tafamidis. about Also

something the arm specific just trial, if endpoint, that Apollo active that your hear in curious endpoints? potentially driven test you who observation. are Billion the in effect benefit treated So could also walk was the or from on emerge I was patients was thoughts cardiovascular six-minute with tafamidis. to that's also think the that And not by to the

the I potential of understand enough TTR. we to saw did overall that not follow in the patient think they what is Apollo benefit long reducing

they So other important do attribute or We be not whether may that or combination the it's to benefit able we this with get small it on matures, to hope arms, was trial factors. saw results. tafamidis that as two hard to differences additional

value fact the be things think they benefit We patients not in that highly over unfortunately, it, So learn silencer by did we that the crossed from lot the but a diluted that tafamidis. other or to placebo about we with of course, about learn rates may patients. didn't trial, and about event

said more up have they we first combinations B with XXXX. of tafamidis. without be should Helios longer tafamidis will which be in it But trial, with the information about the will half coming or much So follow

next Stanley. with Terrence The Flynn Morgan comes question from

now But you to Terrence potential is from needed FlynnMaybe product there going wanted changes in it that's commercial of to this you're make that of ahead used product X. on XXXX for the Phase that you're like were so to just on planned the what the one product? just Phase other post that X, a sounds scale process no ensure obviously as been manufacturing, commercial making clarification everything manufacturing X the you for the use Phase

to we'll who supply. about where Officer stand Chief can Eliana our turn Technical manufacturing the with So talk and Clark, we

you And Yeah. morning. Good thank questions. the for

were going need initiated So we knew Phase to XXXX, patients. we those trial the many X for to when we

X for we people began So the for on the Phase trial.

activities began so facilities and our commercialize. intend we scale up manufacturing to And we process it the the to where bring to

that the it to we already and manufacture mentioned suppose that I majority we the and that in by also manufacturing the in we many clear. and is filed commercial intend changes. the this as we of enter David, that facilities need was setting, commercialization, that for intend take manufacture with setting. we in will commercial FDA anticipate processes both we Glenn We of product And use facilities. to use the don't processes what our Once we included with these making any the we and IND these So

Cheng with The comes J.P. Brian Morgan. next question from

is attributes affect LLB and class [ seen here, cut ] one Phase in the BNP off off how level? distribution pro TTR of potentially cut cut on higher X that NYHA might the than the the baseline your and the higher NT off The in CM. Can comment you

don't did level that healthy, the world because of to patients a they committee idea with have to talking very we your obviously don't contribute leading our in around very no the or course either get XXXX. higher experts choose events hard who is a Yeah, lower our this And are the trial so to no like here It's steering or few they than drug. of the trial. events,

we and trials, be having at say recommend who be the be of trials. in patients events. did should pro average somewhat the we all BPP these that the more We they seeing of in So to Patients think this around sicker risk will all are effects XXXX tends have the valuable drug. should though

So to but important it Most a patients sort most make have we could patients. benefit that patients where leave. it around did of is show are we want to

question next with Minter Blair. William comes The from Myles

for This is Stephanie, Myles. on

question. took Just had We for me just miles. on a quick

would any Do up X Our me additional clinical of of follow modules NTLA-XXXX. planned We for answers study the what that? question be quick details efficacy? a the up those sort took have like follow miles. Phase of on share And you had for [indiscernible] on the from just

seeing work we X about talk some Phase in endpoints Could clinical XXXX? of look forward to the you the from that

Okay, yeah, trial BMP include none MRI that of at and looked the this of in pro heart. we the things

be yet yet. We on cohorts mature. not of the when For want reached do patients most with so And we're to giving that that cardiomyopathy not have patients it's year full one they to guidance available. data have data will

The with next Jay Olson from Oppenheimer. comes question

you on cardiovascular mortality Congrats what to extent According with your progress. reduce a to do deeper the TTR including further silencer? knockdown to relative RNA an events, to models, with expect XXXX

a and given quality, haven't We quantitation of reduction.

there. your hard exactly really answer it's So question that to

Pickering Bernstein. The William comes from next question with

for question. Thanks for aligned interested study on to Huan likely Could with our the over the is investors And year provide information trial you for how magnitude how you keep This runway? your to do cash timeline five three taking Will. in the plan Intellia period?

our want address Glenn, and to do spin you runway? rate

yeah. Sure,

thanks Yeah. the So question. for

So get the with phase but the into XX We're we deep cash talked as to current guiding us not get the study flow next months. will how about, the three. the beyond will get we'll runway how, deep as far we specifically into pretty

Just this is as a the subsidizing XX% costs reminder, here program. Regeneron on of

next question Tuerkcan JMP. with Silvan comes The from

the earnings [ until And on just that call you're about there's XXXX? read wanted to Alnylam’s to ] and think most congrats patisserie I is talk increasing I where regimen, rotisserie a it's dosing there to, into from across on comment likely progress. any switching

XXXX Well, here And is show that. this take premise discussing of efficacy. with doing we're to fundamental today. with about expect study length been is I'll the what The all we John. at that we've that

into time drives also easy that that decisions take And I whatever. take, self-administered only are So secret physician that folks be a don't is going to key patient think are taken what primarily. experience easier infused are that's will are But what single it's true, to it's or medications to than or the doctors that take to consideration. any or

of part XXXX. just It's this. into figures certainly convenience, So

that As their we taking drives look the patients medicine. about much at XXXX patient that very and learned the we've how HAE think population,

for aspect important an it's sure. So

with question comes Lebowitz next The Citi. from David

for on ATTR silencer stabilizer in some the that the how could TTR cardiomyopathy fact patients dealing them for enrollment is point subsequent trial, with would now, even be future, timelines you the one, to and dropping in the a market TAF, consider respect there potential on for the at point. but given which right patients at the With and the criteria number just inclusion also potentially another market

We deal with future. the in potential --

into trial. modify them one protocols stabilizer stabilizers, we be additional able to those patients to allow available, the the So, additional make will

some but course of trial patients for we this designed wild silencer that trial anticipate into in silencers trial on do well. the will that have offer sometime in is For and we as go the a the

insertion AATD it the jumping and candidate. over to and Got

associated various risks considered particular adcom reason is and there this with when focus the on process with that insertion clinical knockdown? be IND the approach to Given the lot needs versus any they certainly to nuance

generally approach who AATD. Laura unique presented been with we can Maybe non-insertion an top can what's candidate, to to recent speak at we the candidate a insertion turn how our versus target targets and analyses versus approaches, just

questions. the for you Thank sure. not I'm Yeah,

any is X of you Factor of inserts whether a for first our guide. programs -- with and start it So

the driven. to be insertions So needs

course, again introduced is by part where on in you spite at broadly. looking particularly look for target it's here our You that of yes, IND the least is very insertion extension selected that teamwork. goal But we that know then more the insertion. your you of of not do for on And Recently that's effective at the have all guides double And trend guide. that look character be location so to but of [indiscernible] target. should side, we're going insertion,

comes Steve Seedhouse Raymond James, next The question ahead go with please from

genomes for question on to Nick a for across was plants ] have patient future have level do you panel even [ some an the in broader related any actually so Acusol target interest for hold is specifically Steve. members? off studies, you edits I see programs CRISPR This year to of it evaluate can

all concur We in That's discussed been It's something regulatory don't. assessment. not think extensively that that be agencies who we informative. would with

from at that taken targets the was how I presented what also probably approach think versus thinking. off we've in the into look that there figures and differ we

with question Canaccord Ijem comes from Genuity. Whitney next The

for question. taking our Juan is on This Thanks for Whitney.

ask trial endpoints your functional and also says is million part take the requiring this? wanted to magnitude I of X what's on preliminary about like guess endpoints Just

as Will include we secondary X-minute a walk tests endpoint.

in endpoint an X-minute be walk our exploratory will trial. test

The second question??

What's endpoints I else secondary the other utility was asked? what think of

most TTR agencies the as high as a secondary secondary Yeah, of important will of life important Reduction well interests is level at both regulatory other TTR places that quality endpoints as think levels. we in as endpoint. be among include well and

turn Ian question-and-answer This I any back concludes the like closing remarks. to to Karp for session. would conference our over

we our and a Okay well, out continuing you to roll your make to update we us. everyone. thanks as Have further great appreciate look We pipeline and again time and for joining forward technologies. progress everyone day,

Thank conference has The attending conference. concluded. now today's for you

disconnect. now You may